These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36671992)

  • 1. Clinical and Neurophysiological Follow-Up of Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with Subcutaneous Immunoglobulins: A Real-Life Single Center Study.
    Alonge P; Di Stefano V; Lupica A; Gangitano M; Torrente A; Pignolo A; Maggio B; Iacono S; Gentile F; Brighina F
    Brain Sci; 2022 Dec; 13(1):. PubMed ID: 36671992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
    Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI
    J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
    Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Ricciardi D; Tedeschi G
    Muscle Nerve; 2019 Dec; 60(6):662-667. PubMed ID: 31415091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis.
    Ramzi A; Maya S; Balousha N; Sabet H; Samir A; Roshdy MR; Aljarrah G; Saleh S; Kertam A; Serag I; Shiha MR
    Neurol Sci; 2024 Jun; ():. PubMed ID: 38937399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages.
    Grüter T; Motte J; Bulut Y; Kordes A; Athanasopoulos D; Fels M; Schneider-Gold C; Gold R; Fisse AL; Pitarokoili K
    Eur J Neurol; 2022 Feb; 29(2):583-592. PubMed ID: 34687104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin.
    Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK
    Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast.
    Desai U
    Neurol Ther; 2023 Oct; 12(5):1409-1417. PubMed ID: 37358694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
    Merkies ISJ; van Schaik IN; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR;
    J Peripher Nerv Syst; 2022 Jun; 27(2):159-165. PubMed ID: 35266243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into refractory chronic inflammatory demyelinating polyneuropathy: a comprehensive real-world study.
    Zheng Y; Hu J; Sun C; Qiao K; Zhao Y; Liu B; Sun J; Xi J; Luo S; Lu J; Zhao C; Lin J
    Front Neurol; 2024; 15():1326874. PubMed ID: 38356878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous "bolus" immunoglobulin dose in CIDP: A proof-of concept study.
    Cocito D; Peci E; Romagnolo A; Rigaldo S; Rosso M; Lopiano L; Merola A
    J Neurol Sci; 2017 Sep; 380():54-57. PubMed ID: 28870589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
    Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
    Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ;
    Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurophysiological Hallmarks of Axonal Degeneration in CIDP Patients: A Pilot Analysis.
    Ricciardi D; Amitrano F; Coccia A; Todisco V; Trojsi F; Tedeschi G; Cirillo G
    Brain Sci; 2022 Nov; 12(11):. PubMed ID: 36358436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
    Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.